Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Sine oculis homeobox homolog 1 (SIX1) is a highly conserved homeodomain-containing transcription factor that belongs to the SIX gene family[1]. The protein is characterized by a divergent DNA-binding homeodomain and an upstream SIX domain, which determines DNA-binding specificity and mediates protein-protein interactions[1]. SIX1 plays a pivotal role during embryogenesis by regulating organogenesis, particularly in the development of muscles, kidneys, ears, and craniofacial structures[5]. The protein functions primarily through interaction with Eyes Absent (EYA) co-activators, forming transcriptional complexes essential for driving developmental programs[2][5]. In normal development, SIX1 regulates the expression of various proteins involved in organ development, including its role in skeletal muscle fiber-type specification and nephron progenitor cell regulation[7]. However, aberrant expression of SIX1 has significant pathological implications. Mutations in the SIX1 gene cause branchio-oto-renal (BOR) and branchio-otic (BO) syndromes, which are characterized by hearing impairment, renal anomalies, and branchial arch defects[2][4]. In cancer contexts, SIX1 acts as a potent oncogene when inappropriately reactivated in adult tissues, contributing to malignant transformation by transcriptionally upregulating cell cycle regulators such as cyclin A1 and cyclin D1, thereby promoting cell proliferation in various cancers including breast and pancreatic carcinoma[3][5]. The protein's transcriptional activity is modulated through post-translational modifications including phosphorylation and ubiquitination, and its function is critically dependent on proper protein-protein interactions and DNA-binding capacity[2][3].
Transcriptional activation, DNA binding, Protein-protein interaction with cofactors
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Sine oculis homeobox homolog 1 (SIX1).